KR20040070331A - 면역약화된 집단에 사용하기 위한 당결합체 백신 - Google Patents

면역약화된 집단에 사용하기 위한 당결합체 백신 Download PDF

Info

Publication number
KR20040070331A
KR20040070331A KR10-2004-7003967A KR20047003967A KR20040070331A KR 20040070331 A KR20040070331 A KR 20040070331A KR 20047003967 A KR20047003967 A KR 20047003967A KR 20040070331 A KR20040070331 A KR 20040070331A
Authority
KR
South Korea
Prior art keywords
antigen
vaccine
polysaccharide
type
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2004-7003967A
Other languages
English (en)
Korean (ko)
Inventor
알리 아이. 파톰
로버트 비. 나소
Original Assignee
나비 바이오파마슈티컬즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나비 바이오파마슈티컬즈 filed Critical 나비 바이오파마슈티컬즈
Publication of KR20040070331A publication Critical patent/KR20040070331A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR10-2004-7003967A 2001-09-19 2002-09-19 면역약화된 집단에 사용하기 위한 당결합체 백신 Ceased KR20040070331A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/955,585 2001-09-19
US09/955,585 US20030113350A1 (en) 2001-09-19 2001-09-19 Glycoconjugate vaccines for use in immune-compromised populations
PCT/US2002/029601 WO2003061558A2 (en) 2001-09-19 2002-09-19 Glycoconjugate vaccines for use in immune-compromised populations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020087022908A Division KR101090529B1 (ko) 2001-09-19 2002-09-19 면역약화된 집단에 사용하기 위한 당결합체 백신

Publications (1)

Publication Number Publication Date
KR20040070331A true KR20040070331A (ko) 2004-08-07

Family

ID=25497036

Family Applications (3)

Application Number Title Priority Date Filing Date
KR10-2004-7003967A Ceased KR20040070331A (ko) 2001-09-19 2002-09-19 면역약화된 집단에 사용하기 위한 당결합체 백신
KR1020087022908A Expired - Lifetime KR101090529B1 (ko) 2001-09-19 2002-09-19 면역약화된 집단에 사용하기 위한 당결합체 백신
KR1020107005839A Expired - Lifetime KR101214766B1 (ko) 2001-09-19 2002-09-19 면역약화된 집단에 사용하기 위한 당결합체 백신

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020087022908A Expired - Lifetime KR101090529B1 (ko) 2001-09-19 2002-09-19 면역약화된 집단에 사용하기 위한 당결합체 백신
KR1020107005839A Expired - Lifetime KR101214766B1 (ko) 2001-09-19 2002-09-19 면역약화된 집단에 사용하기 위한 당결합체 백신

Country Status (11)

Country Link
US (2) US20030113350A1 (https=)
EP (1) EP1427442A4 (https=)
JP (2) JP2005515237A (https=)
KR (3) KR20040070331A (https=)
CN (1) CN1306958C (https=)
CA (1) CA2460749C (https=)
EA (1) EA006602B1 (https=)
MX (1) MXPA04002624A (https=)
NZ (1) NZ548453A (https=)
WO (1) WO2003061558A2 (https=)
ZA (1) ZA200402185B (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100217772B1 (ko) * 1996-09-03 1999-09-01 최진호 조명기기의 램프 과열방지 장치 및 방법
US20020092987A1 (en) * 1998-09-05 2002-07-18 Taehee Cho Photo detect device using quantum dots and materialization method thereof
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
PL229487B1 (pl) 2002-11-12 2018-07-31 Brigham & Womens Hospital Inc Kompozycja zawierająca polimer β-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposób wytwarzania wyodrębnionego polisacharydu, sposób identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego
AU2003298770A1 (en) * 2002-12-02 2004-06-23 Biosynexus Inc Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines
CA2517439C (en) 2003-03-07 2013-07-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
NZ553776A (en) * 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
AU2011265368B9 (en) * 2004-09-22 2012-11-29 Biosynexus Incorporated Immunogenic composition
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
WO2006076058A1 (en) * 2005-01-10 2006-07-20 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
FR2884830A1 (fr) 2005-04-25 2006-10-27 Sanofi Pasteur Sa Procede de production de souches de staphylococcus aureus surproductrices
ES2372537T3 (es) * 2005-07-29 2012-01-23 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Exotoxinas de pseudomonas mutadas con antigenicidad reducida.
EP2476433A1 (en) * 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
FR2899110A1 (fr) * 2006-03-31 2007-10-05 Sanofi Pasteur Sa Polysaccharides capsulaires de type 5 et de type 8 des souches surproductrices de staphylococcus aureus
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
JP5658564B2 (ja) * 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
CN102159540B (zh) 2008-07-21 2015-08-12 布赖汉姆妇女医院 与合成的β-1,6葡糖胺寡糖相关的方法和组合物
WO2010014304A1 (en) * 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
HUE026855T2 (en) 2009-04-03 2016-07-28 Univ Chicago Compositions and methods related to protein a (spa) variants
SA110310528B1 (ar) 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
SG10201406432RA (en) 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
BR112012009014B8 (pt) 2009-09-30 2022-10-04 Novartis Ag Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
HUE034251T2 (en) 2009-10-30 2018-02-28 Glaxosmithkline Biologicals Sa Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
EP2525800B1 (en) * 2010-01-19 2018-07-04 Universitätsklinikum Freiburg Enterococcal cell wall components and antibacterial use thereof
CA2803298C (en) 2010-07-02 2020-07-14 The University Of Chicago Compositions and methods related to protein a (spa) variants
CN102539704A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102565336A (zh) * 2010-12-13 2012-07-11 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102565354A (zh) * 2010-12-13 2012-07-11 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102539708A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102565332A (zh) * 2010-12-13 2012-07-11 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102539726A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102539702A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
US9777076B2 (en) 2012-07-16 2017-10-03 Pfizer Inc. Saccharides and uses thereof
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
AU2015359503B2 (en) 2014-12-10 2019-05-09 Glaxosmithkline Biologicals Sa Method of treatment
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
US12514914B2 (en) 2019-05-14 2026-01-06 The University Of Chicago Methods and compositions comprising Staphylococcus protein a (SpA) variants
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CA3152520A1 (en) * 2019-08-27 2021-03-04 OneBioPharma, Inc. Antimicrobial vaccine compositions
CN114929750B (zh) 2019-09-13 2024-11-22 芝加哥大学 用于治疗葡萄球菌感染的方法和组合物
US20260007731A1 (en) * 2022-01-05 2026-01-08 Bluewillow Biologics, Inc. Intranasal polysaccharide conjugate nanomulsion vaccines and methods of using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747024A (en) * 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen

Also Published As

Publication number Publication date
WO2003061558A3 (en) 2003-09-12
NZ548453A (en) 2007-07-27
EP1427442A2 (en) 2004-06-16
US20030113350A1 (en) 2003-06-19
US7449189B2 (en) 2008-11-11
JP2010265293A (ja) 2010-11-25
EA200400448A1 (ru) 2004-12-30
ZA200402185B (en) 2005-06-29
CN1306958C (zh) 2007-03-28
KR101090529B1 (ko) 2011-12-08
CA2460749C (en) 2012-10-23
CA2460749A1 (en) 2003-07-31
WO2003061558A9 (en) 2004-06-10
KR20080089527A (ko) 2008-10-06
MXPA04002624A (es) 2005-02-17
KR20100044265A (ko) 2010-04-29
KR101214766B1 (ko) 2012-12-24
EP1427442A4 (en) 2006-06-21
WO2003061558A2 (en) 2003-07-31
EA006602B1 (ru) 2006-02-24
JP2005515237A (ja) 2005-05-26
CN1638794A (zh) 2005-07-13
US20060188518A1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
KR101214766B1 (ko) 면역약화된 집단에 사용하기 위한 당결합체 백신
US12605435B2 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
Brett et al. Structural and immunological characterization of Burkholderia pseudomallei O-polysaccharide-flagellin protein conjugates
AU2019215212B2 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
Wessels et al. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine
Austrian Pneumococcal polysaccharide vaccines
Cryz Jr et al. Safety and immunogenicity of Klebsiella pneumoniae K1 capsular polysaccharide vaccine in humans
KR20190055063A (ko) 다가 폐렴구균 다당류-단백질 접합체 조성물
EA037500B1 (ru) Способы и композиции для иммунной защиты против внекишечной патогенной e. coli
JP2631035B2 (ja) 多糖類−タンパク質複合体
KR20190051945A (ko) 다가 폐렴구균 다당류-단백질 접합체 조성물
US20250352631A1 (en) Polyvalent pneumococcal polysaccharide conjugate vaccine component and application thereof
JPH08501563A (ja) グループｂストレプトコッカス・タイプ▲ｉｉ▼およびタイプ▲ｖ▼多糖−蛋白質接合ワクチン
Paoletti et al. Immunogenicity of group B Streptococcus type III polysaccharide-tetanus toxoid vaccine in baboons
AU2002365253B2 (en) Glycoconjugate vaccines for use in immune-compromised populations
Henriksen et al. Vaccination with Protein‐Conjugated and Native Type 3 Capsular Polysaccharide in an Ethanol‐Fed Rat Model of Pneumococcal Pneumonia
NZ531647A (en) Glycoconjugate vaccines for use in immune-compromised populations against Staphylococcal and Enterococcal infections
AU2002365253A1 (en) Glycoconjugate vaccines for use in immune-compromised populations
Naso et al. Polysaccharide conjugate vaccines for the prevention of gram-positive bacterial infections
Lee Capsule and vaccine development
Pozsgay Bacterial polysaccharide-protein conjugate

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040318

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070412

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20080123

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20080721

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20080123

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20080821

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20080721

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20091029

Appeal identifier: 2008101008351

Request date: 20080821

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20080919

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20080919

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20080821

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20080423

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20070412

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
E801 Decision on dismissal of amendment
PB0601 Maintenance of original decision after re-examination before a trial

Comment text: Report of Result of Re-examination before a Trial

Patent event code: PB06011S01D

Patent event date: 20081001

PE0801 Dismissal of amendment

Patent event code: PE08012E01D

Comment text: Decision on Dismissal of Amendment

Patent event date: 20081001

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20080919

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20080423

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20070412

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20080821

Effective date: 20091029

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20091029

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20080821

Decision date: 20091029

Appeal identifier: 2008101008351

J121 Written withdrawal of request for trial
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20091223

PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20091223

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2008101008351

Request date: 20080821

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20091029

WITB Written withdrawal of application